The non-invasive diagnosis of bone turnover in patients with chronic kidney disease (CKD) remains difficult compared with bone histomorphometry as the gold standard. Most clinicians rely on surrogate markers, mainly serum parathyroid hormone and total alkaline phosphatases, in association with serum calcium and phosphorus. Although very high serum PTH levels generally allow the diagnosis of high bone turnover, slight elevations, normal, or low values cannot allow a reliable distinction between normal or low turnover
The guidelines proposed by the Kidney Disease Outcomes Quality Initiative (K/DOQI) suggested that in...
The guidelines proposed by the Kidney Disease Outcomes Quality Initiative (K/DOQI) suggested that in...
Specific measurement of PTH (1-84) in various forms of renal osteodystrophy (ROD) as assessed by bon...
The non-invasive diagnosis of bone turnover in patients with chronic kidney disease (CKD) remains di...
The guidelines proposed by the Kidney Disease Outcomes Quality Initiative (K/DOQI) suggested that in...
peer reviewedParathyroid hormone (PTH) is a key regulator of bone turnover but can be oxidized in vi...
Parathyroid hormone (PTH) is a key regulator of bone turnover but can be oxidized in vivo, which imp...
Parathyroid hormone (PTH) is a key regulator of bone turnover but can be oxidized in vivo, which imp...
BACKGROUND: The management of chronic kidney disease-mineral and bone disorder requires the assessm...
The Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines recommend that serum parathyroid ...
The guidelines proposed by the Kidney Disease Outcomes Quality Initiative (K/DOQI) suggested that in...
New assays for parathyroid hormone (PTH) and the relevance of PTH fragments in renal failure.Backgro...
Background—Determination of parathyroid hormone (PTH) is the most commonly used surrogate marker for...
The guidelines proposed by the Kidney Disease Outcomes Quality Initiative (K/DOQI) suggested that in...
Specific measurement of PTH (1-84) in various forms of renal osteodystrophy (ROD) as assessed by bon...
The guidelines proposed by the Kidney Disease Outcomes Quality Initiative (K/DOQI) suggested that in...
The guidelines proposed by the Kidney Disease Outcomes Quality Initiative (K/DOQI) suggested that in...
Specific measurement of PTH (1-84) in various forms of renal osteodystrophy (ROD) as assessed by bon...
The non-invasive diagnosis of bone turnover in patients with chronic kidney disease (CKD) remains di...
The guidelines proposed by the Kidney Disease Outcomes Quality Initiative (K/DOQI) suggested that in...
peer reviewedParathyroid hormone (PTH) is a key regulator of bone turnover but can be oxidized in vi...
Parathyroid hormone (PTH) is a key regulator of bone turnover but can be oxidized in vivo, which imp...
Parathyroid hormone (PTH) is a key regulator of bone turnover but can be oxidized in vivo, which imp...
BACKGROUND: The management of chronic kidney disease-mineral and bone disorder requires the assessm...
The Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines recommend that serum parathyroid ...
The guidelines proposed by the Kidney Disease Outcomes Quality Initiative (K/DOQI) suggested that in...
New assays for parathyroid hormone (PTH) and the relevance of PTH fragments in renal failure.Backgro...
Background—Determination of parathyroid hormone (PTH) is the most commonly used surrogate marker for...
The guidelines proposed by the Kidney Disease Outcomes Quality Initiative (K/DOQI) suggested that in...
Specific measurement of PTH (1-84) in various forms of renal osteodystrophy (ROD) as assessed by bon...
The guidelines proposed by the Kidney Disease Outcomes Quality Initiative (K/DOQI) suggested that in...
The guidelines proposed by the Kidney Disease Outcomes Quality Initiative (K/DOQI) suggested that in...
Specific measurement of PTH (1-84) in various forms of renal osteodystrophy (ROD) as assessed by bon...